Top US money managers stay upbeat on Chinese stocks amid AI, biotech boom South China Morning Post Politics
Novo adds to obesity drug pipeline via $200M deal with China-based biotech BioPharma Dive Economics
Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech Reuters Economics
Novo licenses Chinese biotech's obesity drug candidate for up to $2 billion Reuters Economics
AstraZeneza Commits Up to $11B+ to Chinese Collaborations, Beijing R&D Hub Genetic Engineering & Biotechnology News Politics
Akeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening. Events
Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US rivalry South China Morning Post Events
Woman feels ‘healthier’ in her zoo role due to active lifestyle, freedom from confines of an office. Society